Advancing technologies for the diagnosis and management of infections

Surgical Clinics of North America

Volumn 94, Issue 6, 2014, Pages 1163-1174

  Heffernan, Daithi S ^a   Fox, Elizabeth D ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Advancing technologies; Diagnosis; Infections; Management

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL DNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIOPHAGE; BACTERIUM CULTURE; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); CULTURE TECHNIQUE; DRUG BIOAVAILABILITY; DRUG DESIGN; HOST PATHOGEN INTERACTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL TECHNOLOGY; META ANALYSIS (TOPIC); MICROARRAY ANALYSIS; MICROFLUIDICS; MICROORGANISM DETECTION; NANOTECHNOLOGY; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL INFECTION; BIOLOGICAL MODEL; CATHETER-RELATED INFECTIONS; DNA MICROARRAY; DNA SEQUENCE; MASS SPECTROMETRY; MICROBIOLOGY; MICROFLUIDIC ANALYSIS; PROCEDURES; SURGICAL WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CATHETER-RELATED INFECTIONS; DNA, BACTERIAL; HUMANS; INFECTION CONTROL; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURGICAL WOUND INFECTION;

EID: 84923183535     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.08.013     Document Type: Review

References (75)

1. Kumar A., Roberts D., Wood K., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
2. Mullins K., Faloona F. Specific synthesis of DNA invitro via a polymerase catalyzed chain reaction. Methods 1987, 155:335-350.
3. Aydiner A., Lusebrink J., Schildgen V., et al. Comparison of two commercial PCR methods for methicillin resistant staphylococcus aureus (MRSA) screening in a tertiary care hospital. PLoS One 2012, 7(9):e43935.
4. Cornut P., Boisset S., Romanet J., et al. Principles and applications of molecular biology techniques for the microbiological diagnosis of acute post-operative endophthalmitis. Surv Ophthalmol 2014, 59(3):286-303.
5. Chaidaroglou A., Manoli E., Marathias E., et al. Use of a multiplex polymerase chain reaction system for enhanced bloodstream pathogen detection in thoracic transplantation. JHeart Lung Transplant 2013, 32(7):707-713.
6. Lodes U., Bohmeier B., Lippert H., et al. PCR-based rapid sepsis diagnosis effectively guides clinical treatment in patients with new onset of SIRS. Langenbecks Arch Surg 2012, 397(3):447-455.
7. Reuter S., Ellington M., Cartwright E., et al. Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern Med 2013, 173(15):1397-1404.
8. Sabat A., Budimir A., Nashev D., et al. Overview of molecular typing methods for outbreak detection and epidemiological surveillance. Euro Surveill 2013, 18(4):20380.
9. Rishishwar L., Petit R.A., Kraft C., et al. Genome sequence based discriminator for vancomycin intermediate staphylococcus aureus. JBacteriol 2014, 196(5):940-948.
10. Fournier P., Drancourt M., Colson P., et al. Modern clinical microbiology: new challenges and solutions. Nat Rev Microbiol 2013, 11(8):574-585.
11. Clark T., Mallard K., Coll F., et al. Elucidating emergence and transmission of multi-drug resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One 2013, 8(12):e83012.
12. Snyder L., Loman N., Faraj L., et al. Epidemiological investigation of Pseudomonas aeruginosa isolates from a six-year long hospital outbreak using high-throughput whole genome sequencing. Euro Surveill 2013, 18(42):20611.
13. Strommenger B., Schmidt C., Werner G., et al. DNA microarray for the detection of therapeutically relevant antibiotic resistance determinants in clinical isolates of Staphylococcus aureus. Mol Cell Probes 2007, 21(3):161-170.
14. Schrenzel J. Clinical relevance of new diagnostic methods for bloodstream infections. Int J Antimicrob Agents 2007, 30(Suppl 1):S2-S6.
15. Otsuka J., Kondoh Y., Amemiya T., et al. Development and validation of microarray based assay for epidemiological study of MRSA. Mol Cell Probes 2008, 22(1):1-13.
16. Minion J., Pai M. Bacteriophage assays for rifampicin resistance detection in mycobacterium tuberculosis: updated meta-analysis. Int J Tuberc Lung Dis 2010, 14(8):941-951.
17. Bhowmick T., Mirrett S., Reller L., et al. Controlled multicenter evaluation of a bacteriophage-based method for rapid detection of staphylococcus aureus in positive blood cultures. JClin Microbiol 2013, 51(4):1226-1230.
18. Sullivan K., Turner N., Roundtree S., et al. Rapid detection of methicillin-resistant staphylococcus aureus (MRSA) and methicillin-susceptible staphylococcus aureus (MSSA) using the KeyPath MRSA/MSSA blood culture and the BacT/ALERT system in a pediatric population. Arch Pathol Lab Med 2013, 137(8):1103-1105.
19. Park S., Zhang Y., Lin S., et al. Advances in microfluidic PCR for point of care infectious disease diagnosis. Biotechnol Adv 2011, 29(6):830-839.
20. Lee W., Kim Y., Chung B., et al. Nano/microfluidics for diagnosis of infectious diseases in developing countries. Adv Drug Deliv Rev 2010, 62(4-5):449-458.
21. Wulff-Burchfield E., Schell W., Eckhardt A., et al. Microfluidic platform versus conventional real time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimens. Diagn Microbiol Infect Dis 2010, 67(1):22-29.
22. Mancini N., De Carolis E., Infurnari L., et al. Comparative evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry systems for identification of yeasts of medical importance. JClin Microbiol 2013, 51(7):2453-2457.
23. Jordana-Lluch E., Carolan H., Gimenez M., et al. Rapid diagnosis of bloodstream infections with PCR followed by mass spectrometry. PLoS One 2013, 8(4):e62108.
24. Jacovides C., Kreft R., Adeli B., et al. Successful identification of pathogens by polymerase chain reaction (PCR) based electron spray ionization time-of-flight mass spectrometry (ESI-TOF-MS) in culture negative peri-prosthetic joint infection. JBone Joint Surg Am 2012, 94(24):2247-2254.
25. Paredes T., Alonso-Arce M., Schmidt C., et al. Smart central venous port for early detection of bacterial biofilm related infections. Biomed Microdevices 2014, 16(3):365-374.
26. Zhang L., Keogh S., Rickard C. Reducing the risk of infection associated with vascular access devices through nanotechnology: a perspective. Int J Nanomedicine 2013, 8:4453-4466.
27. Liu H., Webster T. Mechanical properties of dispersed ceramic nanoparticles in polymer composites for orthopedic applications. Int J Nanomedicine 2010, 5:299-313.
28. Hu C., Fang R., Copp J., et al. Abiomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol 2013, 8(5):336-340.
29. Morley S., Griffiths J., Philips G., et al. Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobial therapy. Br J Dermatol 2013, 168(3):617-624.
30. Prado Montes de Oca E. Antimicrobial peptide elicitors: a new hope for the post-antibiotic era. Innate Immun 2013, 19(3):227-241.
31. Fitzgerald-Hughes D., Devocelle M., Humphreys H. Beyond conventional antibiotics for the future treatment of methicillin resistant staphylococcus aureus infections: two novel alternatives. FEMS Immunol Med Microbiol 2012, 65(3):399-412.
32. van der Does A., Bergman P., Agerberth B., et al. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. JLeukoc Biol 2012, 92(4):735-742.
33. Novak R., Shales D. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 2010, 11(2):182-191.
34. Paukner S., Sader H., Ivezic-Schoenfeld Z., et al. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother 2013, 57(9):4489-4495.
35. Prince W., Ivezic-Schoenfeld Z., Lell C., et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 2013, 57(5):2087-2094.
36. Banyal S., Malik P., Tuli H., et al. Advances in nanotechnology for diagnosis and treatment of tuberculosis. Curr Opin Pulm Med 2013, 19(3):289-297.
37. Suci P., Berglund D., Liepold L., et al. High-density targeting of a viral multifunctional nanoplatform to a pathogenic, biofilm-forming bacterium. Chem Biol 2007, 14(4):387-398.
38. Taylor E., Webster T. Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine 2011, 6:1463-1473.
39. Fayaz A., Girilal M., Mahdy S., et al. Vancomycin bound biogenic gold nanoparticles: a different perspective for development of anti-VRSA agents. Process Biochem 2011, 46:636-641.
40. Gu H., Ho P., Tong E., et al. Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Lett 2003, 3(9):1261-1263.
41. Xing B., Ho P., Yu C., et al. Self-assembled multivalent vancomycin on cell surfaces against vancomycin-resistant enterococci (VRE). Chem Commun (Camb) 2003, 17:2224-2225.
42. Chibeu A., Lingohr E., Masson L., et al. Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. Viruses 2012, 4(4):471-487.
43. Pearson H., Sahukhal G., Elasri M., et al. Phage-bacterium war on polymeric surfaces: can surface-anchored bacteriophages eliminate microbial infections?. Biomacromolecules 2013, 14(5):1257-1261.
44. Magill S., Edwards J., Bamberg W., et al. Multistate point prevalence survey of health care associated infection. NEngl J Med 2014, 370(12):1198-1208.
45. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2003, 2(2):114-122.
46. Kishikawa H., Ebberyd A., Romling U., et al. Control of pathogen growth and biofilm formation using a urinary catheter that releases antimicrobial nitrogen oxides. Free Radic Biol Med 2013, 65:1257-1264.
47. Saint S., Greene M., Damschroder L., et al. Is the use of antimicrobial devices to prevent infection correlated across different healthcare-associated infections? Results from a national survey. Infect Control Hosp Epidemiol 2013, 34(8):847-849.
48. Kollef M., Afessa B., Anzueto A., et al. Silver-coated endotracheal tubes and incidence of ventilator associated pneumonia: the NASCENT randomized trial. JAMA 2008, 300(7):805-813.
49. Machado M., Tarquinio K., Webster T. Decreased Staphylococcus aureus biofilm formation on nanomodified endotracheal tubes: a dynamic airway model. Int J Nanomedicine 2012, 7:3741-3750.
50. Crnich C., Maki D. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I - pathogenesis and short term devices. Clin Infect Dis 2002, 34(9):1232-1242.
51. Mermel L. Prevention of intravascular catheter related infections. Ann Intern Med 2000, 132:391-402.
52. Veenstra D., Saint S., Sahsa S., et al. Efficacy of antiseptic impregnated central venous catheters in preventing catheter related bloodstream infection: a meta-analysis. JAMA 1999, 281:261-267.
53. Maki D., Stolz S., Wheeler S., et al. Prevention of central venous catheter related bloodstream infection by use of an antiseptic impregnated catheter. A randomized controlled trial. Ann Intern Med 1997, 127(4):257-266.
54. Raad I., Darouiche R., Dupuis J., et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997, 127(4):267-274.
55. Roe D., Karandikar B., Bonn-Savage N., et al. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. JAntimicrob Chemother 2008, 61(4):869-876.
56. He W., Wang D., Ye Z., et al. Application of a nanotechnology antimicrobial spray to prevent lower urinary tract infection: a multicenter urology trial. JTransl Med 2012, 10(Suppl 1):S14.
57. Goodman S., Yao Z., Keeney M., et al. The future of biological coatings for orthopedic implants. Biomaterials 2013, 34(13):3174-3183.
58. Li B., Jiang B., Dietz M., et al. Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open fractures. JOrthop Res 2010, 28(1):48-54.
59. Ahn D., Park H., Choi D., et al. The difference of surgical site infection according to the methods of lumbar fusion surgery. JSpinal Disord Tech 2012, 25(8):E230-E234.
60. Chang Z., Hou T., Wu X., et al. An anti-infection tissue engineered construct delivering vancomycin: its evaluation in a goat model of femur defect. Int J Med Sci 2013, 10(12):1761-1770.
61. Edmiston C., Daoud F., Leaper D. Is there an evidence based argument for embracing an antimicrobial (triclosan) coated suture technology to reduce the risk of surgical site infections? A meta-analysis. Surgery 2013, 154(1):89-100.
62. Chang W., Srinivasan V., Morton R., et al. Triclosan-impregnated sutures to decrease surgical site infections: systemic review and meta-analysis of randomized trials. Ann Surg 2012, 255(5):845-859.
63. Dohmen P., Weymann A., Holinski S., et al. Use of an antimicrobial skin sealant reduces surgical site infection in patients undergoing routine cardiac surgery. Surg Infect (Larchmt) 2011, 12(6):475-481.
64. Lipp A., Phillips C., Harris P., et al. Cyanoacrylate microbial sealants for skin preparation prior to surgery. Cochrane Database Syst Rev 2013, (8). CD008062.
65. Fowler V., Allen K., Moreira E., et al. Effect of an investigational vaccine for preventing staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013, 309(13):1368-1378.
66. Long J., Zaborina O., Halbrook C., et al. Depletion of intestinal phosphate after operative injury activates the virulence of P. aeruginosa causing lethal gut-derived sepsis. Surgery 2008, 144(2):189-197.
67. An G. Agent based computer simulation and SIRS: building a bridge between science and clinical trials. Shock 2001, 16(4):266-273.
68. Vodovotz Y., Constantine G., Rubin J., et al. Mechanistic simulations of inflammation: current state and future prospects. Math Biosci 2009, 217(1):1-10.
69. An G., Mi Q., Dutta-Moscato J., et al. Agent based models in translational systems biology. Wiley Interdiscip Rev Syst Biol Med 2009, 1(2):159-171.
70. Gopalakrishnan V., Kim M., An G. Using an agent based model to examined the role of dynamic bacterial virulence potential in the pathogenesis of surgical site infection. Adv Wound Care (New Rochelle) 2013, 2(9):510-526.
71. Folcik V.A., An G.C., Orosz C.G. The basic immune simulator: an agent based model to study the interactions between innate and adaptive immunity. Theor Biol Med Model 2007, 4:39.
72. Fischer N., Raunest M., Schmidt T., et al. Efflux pump-mediated antibiotics resistance: insights from computational structural biology. Interdiscip Sci 2014, 6(1):1-12.
73. Stern J., Olivas A., Valuckaite V., et al. Agent based model of epithelial host pathogen interactions in anastomotic leak. JSurg Res 2013, 184(2):730-738.
74. Arciero J., Ermentriut B., Upperman J., et al. Using a mathematical model to analyze the role of probiotics and inflammation in necrotizing enterocolitis. PLoS One 2010, 5(4):e10066.
75. Kim M., Christley S., Alverdy J., et al. Immature oxidative stress management as a unifying principle in the pathogenesis of necrotizing enterocolitis: insights from an agent-based model. Surg Infect (Larchmt) 2012, 13(1):18-32.